Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Avalo Therapeutics (AVTX) Revenue (2016 - 2025)

Avalo Therapeutics' Revenue history spans 12 years, with the latest figure at $59000.0 for Q4 2025.

  • For Q4 2025, Revenue fell 69.27% year-over-year to $59000.0; the TTM value through Dec 2025 reached $59000.0, down 86.62%, while the annual FY2025 figure was $59000.0, 86.62% down from the prior year.
  • Revenue reached $59000.0 in Q4 2025 per AVTX's latest filing, down from $192000.0 in the prior quarter.
  • In the past five years, Revenue ranged from a high of $14.9 million in Q3 2022 to a low of $59000.0 in Q4 2025.
  • Average Revenue over 5 years is $1.7 million, with a median of $571000.0 recorded in 2023.
  • Peak YoY movement for Revenue: soared 1007.33% in 2022, then crashed 98.42% in 2023.
  • A 5-year view of Revenue shows it stood at $219000.0 in 2021, then skyrocketed by 309.13% to $896000.0 in 2022, then crashed by 36.27% to $571000.0 in 2023, then crashed by 66.37% to $192000.0 in 2024, then tumbled by 69.27% to $59000.0 in 2025.
  • Per Business Quant, the three most recent readings for AVTX's Revenue are $59000.0 (Q4 2025), $192000.0 (Q4 2024), and $249000.0 (Q3 2024).